Tenofovir alafenamide versus Tenofovir disoproxil: systematic review and meta-analysis (protocol).

Abstract

Highly active antiretroviral therapy (HAART) has greatly reduced morbidity and mortality, resulting in high survival rates among infected patients. Despite the impact of HAART, mortality in successfully treated HIV infected patients remains higher than in the general uninfected population. The effects of persistent inflammation and drug toxicity on comorbidities that are considered non-HIV related, including metabolic, cardiovascular and renal disease, contribute to these differences in the health of infected individuals New Reference. Among antiretroviral moleculars, tenofovir disoproxil is widely used.

Tenofovir alafenamide is a new oral prodrug of tenofovir, a nucleotide analogue that inhibits HIV-1 transcription. Tenofovir alafenamide has potential intracellular accumulation; lower extracellular exposures of tenofovir may be realized with the potential to reduce off-target toxicities. Specifically, lower drug exposures to kidney cells may provide for fewer renal complications as observed in a minority of patients treated with tenofovir disoproxil fumarate.